Prasugrel hcl manufacturers?

Who Makes Prasugrel HCl?

Prasugrel HCl, an antiplatelet medication, is sold under various brand names such as Effient. It is a synthetic P2Y12 inhibitor, used to treat patients with acute coronary syndrome (ACS) or myocardial infarction.

Approved Manufacturers

The U.S. Food and Drug Administration (FDA) has approved several manufacturers to produce Prasugrel HCl. [1] These include:

- Daiichi Sankyo, Inc. - Effient [2]
- Eon Labs, Inc., a subsidiary of Teva Pharmaceutical Industries - Effient [3]
However, there is limited data on other companies' involvement.

Patent Exclusivity

Prasugrel's patent exclusivity is set to expire in 2029. [4] Once the exclusivity expires, generic versions of the drug can enter the market. Companies like Mylan, Teva Pharmaceuticals, and Sandoz have expressed interest in producing generic Prasugrel versions.

Biosimilar Development

Biosimilars of Prasugrel are being developed, but these products are not yet approved by the FDA. Biosimilars are biological products that are highly similar to a reference product. These versions aim to provide a more cost-effective treatment option.

Important Note

Please consult a healthcare professional before making any decisions regarding drug treatments. This information is for general purposes only.

Sources:

[1] DrugPatentWatch.com - Prasugrel HCl Patent Overview https://www.drugpatentwatch.com/patents/Prasugrel-HCl/US-20090135759

[2] Daiichi Sankyo, Inc. - Effient (Daiichi Sankyo, Inc.)

[3] Eon Labs, Inc. - Effient (Eon Labs, Inc.)

[4] DrugPatentWatch.com - Prasugrel HCl Patent Expiration Date https://www.drugpatentwatch.com/patents/Prasugrel-HCl/US-20090135759/expiration_date